Veracyte (NASDAQ:VCYT) SVP Annie Mcguire Sells 2,283 Shares

Key Points

• Annie Mcguire, Senior Vice President of Veracyte, sold 2,283 shares of the company's stock for approximately $76,914, decreasing her ownership by 2.43%.
• Veracyte's stock price increased by 0.6% to $34.15, with the company holding a market cap of $2.69 billion and a price-to-earnings ratio of 103.49.
• Institutional investors have shown increased interest in Veracyte, with firms like Xponance Inc. and Blair William & Co. boosting their stakes in the company by 5.7% and 3.5% respectively.

Veracyte, Inc. (NASDAQ:VCYT - Get Free Report) SVP Annie Mcguire sold 2,283 shares of the business's stock in a transaction that occurred on Friday, September 19th. The shares were sold at an average price of $33.69, for a total transaction of $76,914.27. Following the transaction, the senior vice president directly owned 91,599 shares of the company's stock, valued at approximately $3,085,970.31. This represents a 2.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Veracyte Stock Up 0.6%

Shares of Veracyte stock traded up $0.22 during trading on Tuesday, reaching $34.15. The company's stock had a trading volume of 748,144 shares, compared to its average volume of 1,146,504. The firm's 50-day moving average is $28.44 and its two-hundred day moving average is $28.92. Veracyte, Inc. has a 52-week low of $22.61 and a 52-week high of $47.32. The company has a market cap of $2.69 billion, a price-to-earnings ratio of 103.49 and a beta of 2.07.

Hedge Funds Weigh In On Veracyte

Institutional investors and hedge funds have recently made changes to their positions in the stock. Xponance Inc. increased its stake in Veracyte by 5.7% in the first quarter. Xponance Inc. now owns 6,860 shares of the biotechnology company's stock valued at $203,000 after purchasing an additional 370 shares during the period. Blair William & Co. IL grew its holdings in Veracyte by 3.5% in the first quarter. Blair William & Co. IL now owns 16,092 shares of the biotechnology company's stock valued at $477,000 after purchasing an additional 550 shares during the period. California State Teachers Retirement System increased its holdings in Veracyte by 0.8% in the 2nd quarter. California State Teachers Retirement System now owns 71,095 shares of the biotechnology company's stock valued at $1,922,000 after purchasing an additional 566 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Veracyte by 4.6% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 17,991 shares of the biotechnology company's stock valued at $486,000 after purchasing an additional 790 shares during the period. Finally, Versant Capital Management Inc increased its holdings in shares of Veracyte by 1,267.6% in the 1st quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 862 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have commented on VCYT shares. Morgan Stanley set a $28.00 price target on Veracyte and gave the stock an "underweight" rating in a research report on Friday, August 8th. Wall Street Zen upgraded Veracyte from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Veracyte has an average rating of "Moderate Buy" and an average target price of $40.90.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.